Skip to main content

KOD

Stock

KOD

Stock
Health Care
Biotechnology

Performance overview

KOD Price
Price Chart

Forward-looking statistics

Beta
2.06
Risk
96.91%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Company info

SectorHealth Care
IndustryBiotechnology
Employees106
Market cap$151.8M

Fundamentals

Enterprise value$125.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity62.14

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.62
Dividend per share
Revenue per share
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth-6.1
Credit+14.1
Liquidity+1.8
Inflation-10.6
Commodities-1.7
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-1.04
Price to sales
P/E Ratio-1.04
Enterprise Value to Revenue
Price to book1.91

Upcoming events

Next earnings dayAugust 12, 2025
Next dividend day
Ex. dividend day

News

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 13, 2025)
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases.

Benzinga (December 9, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free